Login / Signup

Open-Label, Multicenter, Phase I/II, First-in-Human Trial of TK216: A First-Generation EWS::FLI1 Fusion Protein Antagonist in Ewing Sarcoma.

Paul A MeyersNoah FedermanNajat C DawPeter M AndersonLara E DavisAeRang KimMargaret E MacyAngela PietrofesoRavin RatanRichard F RiedelMatteo TruccoJames B BreitmeyerJeffrey A ToretskyJoseph A Ludwig
Published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
TK216 administered as 14-day continuous infusion with or without vincristine was well tolerated and showed limited activity at the RP2D in R/R ES.
Keyphrases
  • open label
  • phase iii
  • phase ii
  • clinical trial
  • study protocol
  • endothelial cells
  • induced pluripotent stem cells
  • low dose
  • double blind
  • pluripotent stem cells
  • randomized controlled trial
  • phase ii study
  • cross sectional